@juliankissa@DeryaTR_ I think its overrated in terms of generalized longevity now. It can definitely provide data that can lead scientists to develop protocol. The recs all the llms make now regarding longevity are way off. They are good at certain things like radiology and combing through data
Aging is arguably the root cause of most major diseases (loss of function in our cells). Four years ago, we made a bet that aging was treatable, and NewLimit was born.
NewLimit now has a prototype drug that reverses the age of some human cells (restores function they had when they were younger), and a clinical trial scheduled for next year (with more drug candidates in the pipeline).
Grateful to Founders Fund, Thrive, Greenoaks, and the rest of the investors for this latest round. @jacobkimmel and the team are just getting started.
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
DSIP was studied to try and induce sleep but the results were underwhelming
Sleep is a complex orchestra that require multi body systems and different parts of the brain to coordinate
Central and peripheral clocks, sympathetic/parasympathetic nervous system
The peptide folks flame ‘big pharma’ for “one pill for one problem” but then engage in the same shilling for peptides
If you’ve seen the ads for a GRAIL Galleri blood test that screens for 50+ cancers at once and wondered whether to get one, the biggest trial yet just reported real numbers. 142,250 people. What it actually does for you, in plain terms:
Screen 1,000 people.
-> About 9 get a “cancer signal found” letter.
-> Around 5 of them really have cancer, and some are caught early, before any symptom.
-> The other 4 get the fear and a round of scans that turn up nothing.
-> The test also stays quiet for about half the cancers that are truly there, so a clean result is not an all-clear.
Where it earns its keep is catching cancer earlier. More found at a stage you can still treat, fewer found after they’ve already spread, and a quarter fewer people learning they have cancer by collapsing into an emergency room.
Now the part it has not shown. Whether any of this makes people live longer. That trial is still running, so we genuinely don’t know yet. Worth knowing before you pay for one.